Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Raises $9.9M in Series C Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discovery has closed a Series C round of financing, raising £6.25 million ($9.9 million).

The Cambridge, UK-based firm said the funds will be used to improve its core Genesis and X-Man technology platforms, address new markets, and begin targeting therapeutics outside of its initial focus on cancer. Its Genesis technology is a virally-mediated , gene-engineering technology, and its X-Man models are genetically-defined, patient-relevant human cells lines used for modeling disease-causing mutations in cancer patients.

The round was led by European venture capital firm DFL Esprit. Other investors included Roche Venture Fund, Jonathan Milner, and David Evans, who currently is chairman of Immunodiagnostics Systems.

As part of the financing, Horizon appointed DFJ Esprit Partner Nigel Pitchford to its board as investor director and Evans as non-executive director.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.